Introduction: Little is known about the clinical characteristics and management of type 1 diabetes (T1D) in Spain from a national perspective. To sort this lack of information out the Spanish Diabetes Society (SED) promoted a national population-based audit study. (SED1 Study).

Material and Methods: Observational, cross-sectional study of a nationally representative sample of patients with DM1 in 78 Spanish sites, including children and adults.

Results: A total of 647 participants were included: Aged 36.5+14.4 years (7.6% < 14), 55,3% female, 97.2% Caucasian, time since diagnosis 17.9±12.0 years and a BMI of 24.7±4.4 kg/m2 (40.2% > 25; 12.1% ≥30). 75.0% of the population had secondary or university studies. 20.2% of patients were active smokers and 48.7% had any type of comorbidity, mainly dyslipidemia (25.8%). Any kind of retinopathy and nephropathy was present in 19.3 and 5.9% of patients. Regarding disease management, 75.9% used basal-bolus insulin therapy, 20.4% pump therapy, half of patients used insulin/carbohydrate ratio (ICR), performed 3.0±0.9 blood glucose measurements/day (BG) and 24.9% used continuous-glucose monitoring. Mean last-year HbA1c was 7.6±1.2% (< 7%, 30.6%). The univariate logistic regression indicated that, HbA1c value was determined negatively by BG measurements (-0.045, p=0.03) and frequency of use of ICR (-0.236, p=0.008) and positively by disease duration (0.011, p=0.002) and lack of adherence to diet counseling (0.788, p=0.0001).

Conclusion: The management and type of treatment of T1D in Spain is similar to other western countries. There is still a substantial proportion of patients not reaching the recognized A1c target and with either overweight or obesity. Some factors related to T1D management prevent a greater effectiveness of treatment.


F. Gomez-Peralta: Advisory Panel; Self; Abbott, Novo Nordisk A/S, Sanofi. Speaker's Bureau; Self; Abbott, AstraZeneca, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S. E. Menéndez-Torre: None. S. Conde Barreiro: Other Relationship; Self; Lilly Diabetes, Sanofi. I. Conget: None. A. Novials: None.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at